Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by claims that Agilon Health may have misled investors regarding its business performance [1]. - Shareholders who purchased Agilon Health securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Company Performance - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025, and the company suspended its full-year 2025 financial guidance [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms in this area since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - Shareholders who purchased Agilon Health securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2]. - Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025, following the announcement of the suspension of its full-year 2025 financial guidance due to unexpected industry headwinds [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by claims that Agilon Health may have misled investors regarding its business performance [1]. - Shareholders who purchased Agilon Health securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. Group 2: Company Performance - On August 4, 2025, Agilon Health announced its second quarter results, indicating that industry headwinds were more severe than previously anticipated [3]. - Following this announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 3: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of achieving substantial settlements for investors, including over $438 million in 2019 alone [4].

Company Overview - Agilon Health partners with primary care doctors to deliver coordinated, value-based senior care [3] Allegations and Financial Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Agilon Health due to allegations of providing potentially misleading business information [1] - On August 4, 2025, Agilon Health announced its second-quarter 2025 results, with the Executive Chair acknowledging that industry challenges had become more severe than expected, leading to the suspension of its full-year financial guidance [4] - Following this announcement, Agilon Health's stock plummeted by 51.5% on August 5, 2025 [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by claims that Agilon Health may have provided misleading information to investors [1]. - Shareholders who purchased Agilon Health securities may be entitled to compensation through a class action without any out-of-pocket fees [2]. Group 2: Company Performance - On August 4, 2025, Agilon Health reported its second-quarter results, indicating that industry headwinds were more severe than previously anticipated [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 3: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by claims that Agilon Health may have misled investors regarding its business performance [1]. - Shareholders who purchased Agilon Health securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. Group 2: Company Performance - On August 4, 2025, Agilon Health reported its second-quarter results, indicating that industry headwinds were more severe than previously anticipated [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025, and the company suspended its full-year 2025 financial guidance [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Points - Agilon Health's shares fell 6.8% after receiving a non-compliance notice from the New York Stock Exchange due to its stock price dropping below listing standards [1][2] - The notice was triggered by the stock's average closing price remaining below $1.00 for a continuous 30-day period, following a larger-than-expected loss reported in the third quarter [2] - To avoid delisting, Agilon Health plans to seek a reverse stock split, pending stockholder approval, and has a six-month period to regain compliance [2] - A Barclays analyst also lowered the price target on Agilon Health's stock, contributing to negative sentiment [2] Financial Performance - In the third quarter, Agilon Health reported revenue of $1.44 billion, a 1.1% year-over-year decline, but narrowly exceeded analyst estimates [5] - The company posted a GAAP loss of $0.27 per share, missing the consensus estimate of a $0.17 loss, indicating significant profitability issues [5] - Full-year revenue guidance was in line with expectations, but the outlook for adjusted EBITDA was well below analyst projections [5] Stock Performance - Agilon Health's shares have experienced extreme volatility, with 77 moves greater than 5% over the last year, indicating the market views recent news as significant but not fundamentally altering its perception of the business [4] - The stock is down 65.1% year-to-date and is trading at $0.67 per share, which is 88.2% below its 52-week high of $5.68 from April 2025 [6] - An investment of $1,000 in Agilon Health's shares at the IPO in April 2021 would now be worth $21.60 [6]

Core Viewpoint - The law firm Shamis & Gentile, P.A. is investigating potential breaches of fiduciary duties by directors and officers of agilon health, inc. following a significant drop in the company's stock price due to lowered profit forecasts and increased medical costs [1][2]. Group 1: Investigation Details - The investigation is prompted by agilon health's unexpected announcement on January 5, 2024, which included a reduction in its 2023 profit forecasts, specifically lowering its Medical Margin and Adjusted EBITDA guidance due to higher than anticipated medical costs [2]. - Following the announcement, agilon's stock price fell by $3.45, or 28.6%, closing at $8.63 on the same day [2]. - A securities class action lawsuit has been filed against agilon and certain executives, alleging that they misled investors regarding medical costs and provided overly optimistic financial guidance [3]. Group 2: Governance and Oversight - Shamis & Gentile, P.A. is assessing whether agilon's board of directors and senior executives failed to maintain adequate oversight and internal controls related to the alleged misconduct, which may have led to significant legal, financial, and reputational risks for the company [4]. - Long-term shareholders may have the opportunity to seek corporate governance reforms and the return of funds to the company, with no associated costs [5].

Core Viewpoint - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article highlights that users may face access issues if they have an ad-blocker enabled [1] - It suggests disabling ad-blockers and refreshing the page to proceed [1]

Core Insights - Agilon Health (AGL) reported a quarterly loss of $0.27 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, marking an earnings surprise of -50.00% [1] - The company generated revenues of $1.44 billion for the quarter ended September 2025, slightly surpassing the Zacks Consensus Estimate by 0.57%, but down from $1.45 billion a year ago [2] - Agilon shares have declined approximately 57.4% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Agilon has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $1.47 billion, and for the current fiscal year, it is -$0.56 on revenues of $5.82 billion [7] Market Outlook - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical Services industry, to which Agilon belongs, is ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8]